ArticleNeuropsychopharmacology reports2026
Development of Japanese Versions of the 4-Item Mystical Experience Questionnaire and 7-Item Challenging Experience Questionnaire.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionInterest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ-4 and CEQ-7.
methodsIn translating the MEQ-4 and CEQ-7, our procedures were informed by the recommendations of the "Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation." Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese-speaking sample with psychedelic experience was not feasible.
resultsThe final, approved back-translated versions of the MEQ-4 and CEQ-7 were developed, and the authorized Japanese versions of the MEQ-4 and CEQ-7 were established.
conclusionsIn the present study, Japanese versions of the MEQ-4 and CEQ-7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese-speaking samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.